Shares of the bio-pharmaceutical company plunged as much as 6% to Rs 982, lowest since January 2017.
U.S. FDA issued form 483 with 8 observations to company's Bengaluru facility. Biocon said it responded to drug regulator on all observations.
Volume at 10 times its 30-day average.